Imatinib mesylate and nilotinib decrease synthesis of bone matrix
bone
chronic myeloid leukemia
imatinib
nilotinib
osteoblastogenesis
receptor activator of nuclear factor κB ligand
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
23
08
2018
accepted:
13
05
2019
entrez:
20
8
2019
pubmed:
20
8
2019
medline:
20
8
2019
Statut:
ppublish
Résumé
Tyrosine kinase inhibitors (TKIs), such as imatinib (IMA) and nilotinib (NIL), are the cornerstone of chronic myeloid leukemia (CML) treatment via the blockade of the oncogenic
Identifiants
pubmed: 31423283
doi: 10.3892/ol.2019.10518
pii: OL-0-0-10518
pmc: PMC6614669
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2102-2108Références
N Engl J Med. 2001 Apr 5;344(14):1031-7
pubmed: 11287972
Cancer Lett. 2003 Apr 25;193(2):161-70
pubmed: 12706873
Blood. 2004 Nov 1;104(9):2655-60
pubmed: 15231574
Leukemia. 2006 Feb;20(2):187-92
pubmed: 16341042
Blood. 2006 Sep 1;108(5):1478-84
pubmed: 16627756
N Engl J Med. 2006 May 11;354(19):2006-13
pubmed: 16687713
N Engl J Med. 2006 Jun 15;354(24):2542-51
pubmed: 16775235
Biol Blood Marrow Transplant. 2006 Aug;12(8):795-807
pubmed: 16864049
J Pathol. 2007 Apr;211(5):555-62
pubmed: 17323424
Cell Prolif. 2007 Jun;40(3):355-66
pubmed: 17531080
Arthritis Res Ther. 2007;9 Suppl 1:S1
pubmed: 17634140
J Bone Miner Res. 2007 Nov;22(11):1679-89
pubmed: 17663639
Blood. 2008 Mar 1;111(5):2538-47
pubmed: 18042796
Leuk Res. 2008 Jun;32(6):980-3
pubmed: 18191450
Expert Opin Investig Drugs. 2008 Jul;17(7):1127-36
pubmed: 18549348
J Clin Endocrinol Metab. 2009 Apr;94(4):1131-6
pubmed: 19174494
Exp Hematol. 2009 Apr;37(4):461-8
pubmed: 19302920
Rev Esp Cardiol. 2009 Apr;62(4):354-64
pubmed: 19401120
Blood. 2010 Jan 28;115(4):766-74
pubmed: 19890095
Calcif Tissue Int. 2011 Jan;88(1):16-22
pubmed: 20978751
Pediatr Blood Cancer. 2011 Apr;56(4):671-3
pubmed: 21298759
Hematol Oncol. 2012 Mar;30(1):27-33
pubmed: 21544849
J Pediatr. 2011 Oct;159(4):676-81
pubmed: 21592517
BMC Res Notes. 2011 Oct 14;4:410
pubmed: 21996334
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Cancer Chemother Pharmacol. 2013 Feb;71(2):531-6
pubmed: 23183914
Med Sci Monit. 2012 Dec;18(12):CR721-8
pubmed: 23197234
Pediatr Blood Cancer. 2013 Jul;60(7):1148-53
pubmed: 23322583
Nat Med. 2013 Feb;19(2):179-92
pubmed: 23389618
Eur J Cancer. 2014 Dec;50(18):3206-11
pubmed: 25459396
Mol Med Rep. 2015 Apr;11(4):3143-7
pubmed: 25501030
PLoS One. 2015 Jun 24;10(6):e0131192
pubmed: 26107505
Am J Transl Res. 2016 Jul 15;8(7):3133-40
pubmed: 27508034
PLoS One. 2016 Oct 13;11(10):e0164727
pubmed: 27737004
Int J Hematol. 2017 Feb;105(2):196-205
pubmed: 27766528
Mol Med Rep. 2018 Jan;17(1):1382-1388
pubmed: 29115640
Leukemia. 2018 Jul;32(7):1657-1669
pubmed: 29925908
Nat Med. 1996 May;2(5):561-6
pubmed: 8616716